Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiviral Therapy Combined With Novel Immunotherapy for Chronic Hepatitis B
NCT06777173Enrolling by invitation
- Sponsor
- Beijing Ditan Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Randomised trial in Chronic Hepatitis B (CHB) (5 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: HBsAg clearance at 48 weeks. Started Dec 2023; status: enrolling by invitation.
02
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06777173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777173.